LineaRx, Inc.的动态

In the 21st century, we’ve seen substantial progress in the management of ANCA-associated #vasculitis, with a shift away from cytotoxic therapies in favor of more targeted drugs and #biologics like rituximab and avacopan. Despite developments, the mortality rate for these patients is 2-3x higher than for the general population, and patients often suffer as much from #SteroidToxicty as from the underlying disease. Learn why ?? https://hubs.li/Q02rvP0s0 #AutoimmuneDiseaseManagement #SteritasGTI #SteroidToxicityAwareness #VasculitisTreatment #SteroidInducedComplications

#Pharmacogenetictesting involves analyzing an individual’s genetic makeup to understand how they will respond to specific medications. This personalized approach helps optimize drug efficacy, minimize adverse effects, and tailor treatments based on genetic variations. It plays a crucial role in #precisionmedicine, improving treatment outcomes and patient safety. To know more about the market, https://lnkd.in/dV5JQCTz #DBMR #Pharmacogenetics #PersonalizedMedicine #GeneticTesting #PrecisionMedicine #HealthcareInnovation #Genomics #DNAAnalysis #MedicalTesting #Pharmacology #Bioinformatics #GeneTherapy #HealthTech #PharmacogenomicTesting #DBMRInsights?

Prevent Blindness recently hosted a webinar on the importance of genetic testing for inherited retinal diseases. Read more about the topics covered below. #InheritedRetinalDisease #InheritedRetinalDiseases #GeneticTesting The Janssen Pharmaceutical Companies of Johnson & Johnson

Can genetically engineered phages be the solution to treating intracellular bloodstream E. coli infections? Antonia Sagona from the University of Warwick will discuss her lab's methods for modifying Ε. coli bacteriophages to better target human cells and intracellular bacteria during #TargetingPhagTherapy2024. ?? Dr. Sagona will present novel, unpublished data on phages targeting clinical bloodstream E. coli samples from UCWH hospital patients, aiming to enhance their efficiency in invading human cells and clearing infections. ?? Learn more in conference agenda: https://lnkd.in/dWirnDTM Join us at the 7th World Congress Targeting Phage Therapy to learn more about these innovative approaches. #PhageTherapy #QualityControl #Pharmaceuticals #TargetingPahgeTherapy #TPT2024

In the 21st century, we’ve seen substantial progress in the management of ANCA-associated #vasculitis, with a shift away from cytotoxic therapies in favor of more targeted drugs and #biologics like rituximab and avacopan. Despite developments, the mortality rate for these patients is 2-3x higher than for the general population, and patients often suffer as much from #SteroidToxicty as from the underlying disease. Learn why ?? https://hubs.li/Q02rvLtp0 #AutoimmuneDiseaseManagement #SteritasGTI #SteroidToxicityAwareness #VasculitisTreatment #SteroidInducedComplications

We are proud to announce positive Phase 1b clinical trial results for SOR102, our first-in-class oral biologic for ulcerative colitis. This study marks the first successful demonstration of an orally dosed antibody delivering clinical efficacy, showing statistically significant improvements across multiple clinical endpoints, with a favorable safety and tolerability profile. As our CEO, Ciara Kennedy, shared: “SOR102 represents a game changer in the treatment of inflammatory bowel disease. By combining efficacy and convenience in an oral therapy, we aim to transform the standard of care and improve the lives of patients living with ulcerative colitis.” We are excited to advance SOR102 into Phase 2 development in 2025 and continue building on this milestone. Read the press release here: https://lnkd.in/d_8C-TgK Also see this exclusive article by Max Gelman in Endpoints News: https://lnkd.in/dHwgxs9Y #UlcerativeColitis #IBD #ClinicalTrials #AutoimmuneDisease #DrugDevelopment #Biologics #OralTherapies #CombinationTherapy

Intimate knowledge of TA and lead candidate toxicity potential can never be understated and lack of insight can make or break a study and potentially an entire program. Emulate, Inc. human liver chips correctly predicted toxicity with sensitivity of 87% and a specificity of 100% in a recent study in Nature Communications Medicine, statistics which are significantly greater than the next best option - animal studies Don't wait until trials to find out about human toxicity of your compound - start learning about it in human liver organ chips and find the pertinent negative faster #emulate #organonchip #liverchips #toxicity #DILI #microphysiologicalsystems #MPSworldsummit

Before the launch of a first-to-market rare disease therapy, a global pharmaceutical company decided to implement a genetic test result review program to ensure that patients whose healthcare provider submitted a product enrollment form had a genetic report consistent with the genetic indication and contraindication in the prescribing information. Because of the high complexity of the eligibility requirements, the company recognized the need for external genetics expertise to build and support a fully operationalized genetic eligibility verification program. Learn what happened when this company partnered with us to support its commercial launch! https://lnkd.in/gkfURd-W #lifesciences #genetics

https://lnkd.in/gpH84aGs Article Title: BAT’s specific Micro-RNA or Novel approach for treatment of obesity: A hypothesis Author(s): Arefhosseini Seyed Rafie*, Farsad Laiegh Amirali, Jazar Hassan and Alijani Sepideh Journal: International Journal of Pharmaceutical Sciences and Developmental Research Journal ISSN: 2640-7760 Abstract Background: Type 2 Diabetes (T2D) is associated with coronary microvascular dysfunction, which is thought to contribute to compromised diastolic function, ultimately culminating in heart failure with preserved ejection fraction (HFpEF). The molecular mechanisms remain incompletely understood, and no early diagnostics are available. We sought to gain insight into biomarkers and potential mechanisms of microvascular dysfunction in obese mice (db/db) and lean rats (Goto-Kakizaki) pre-clinical models of T2D-associated diastolic dysfunction. #Biomarker #Diabetes #Diastolicdysfunction #Endothelialcell #Extracellularvesicle#Heartfailurewithpreservedejectionfraction #Microvasculature #microRNA #Obesity #miRNA22 #BAT #MedicinalChemistry #DrugDevelopment #Pharmacokinetics #Pharmacodynamics #Pharmacogenomics #Toxicology #Pharmaceutics #Biopharmaceutics #Pharmacognosy #PharmaceuticalChemistry #PharmacyPractice #CommunityPharmacy #HospitalPharmacy #IndustrialPharmacy #RegulatoryAffairs #DrugFormulation#DrugDelivery #PharmacyManagement #PharmaceuticalTechnology #PharmacyEducation #ClinicalTrials

The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' (VRTX.O) next-generation treatment for a rare and progressive genetic disease, the company said on Friday, expanding its dominance in the market for cystic fibrosis.